Foghorn Therapeutics (FHTX)
(Delayed Data from NSDQ)
$5.02 USD
-0.12 (-2.33%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $5.01 -0.01 (-0.20%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
FHTX 5.02 -0.12(-2.33%)
Will FHTX be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for FHTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for FHTX
Alnylam (ALNY) Surges 6.0%: Is This an Indication of Further Gains?
Wall Street Analysts Predict a 130.63% Upside in Foghorn Therapeutics (FHTX): Here's What You Should Know
FHTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Is Arcutis Biotherapeutics (ARQT) Stock Outpacing Its Medical Peers This Year?
Foghorn Therapeutics (FHTX) Upgraded to Buy: Here's Why
Here's Why Foghorn Therapeutics (FHTX) Looks Ripe for Bottom Fishing
Other News for FHTX
Is FHTX gaining bullish strength? 200 Day Moving Average Support shows up after slipping 2.33%
Is FHTX gaining bullish strength? Crossed Above 200 Day Moving Average shows up after soaring 7.08%
FHTX Fell Below 200 Day Moving Average on September 18
Foghorn Therapeutics (FHTX) Receives Buy Rating with $10 Target
Foghorn Therapeutics transferred with Buy rating at B. Riley